Mycobacterium tuberculosis is the cause of tuberculosis (TB), a granulomatous illness that mostly affects the lungs. Pakistan is one of the eight nations that accounts for two-thirds of all new cases of developing TB. TB has long been an endemic disease in Pakistan. According to the World Health Organization (WHO) estimates, the nation has over 500 000 incident TB infections per year, with a rising number of drug-resistant cases. Recently, the coexistence of COVID-19 and TB in Pakistan has provided doctors with a problem. Fever or chills, cough, shortness of breath or difficulty breathing are all signs of COVID-19. After SARS-CoV-2 infection, cough might persist for weeks or months and it is frequently accompanied by persistent tiredness, cognitive impairment, dyspnoea or pain – a group of long-term consequences known as post-COVID syndrome or protracted COVID. Coughing with mucus or blood, and coughing that continues over 2 months are indications of TB. The same clinical presentation features make it difficult for healthcare personnel to effectively evaluate the illness and prevent the spread of these fatal diseases. Pakistan lacks the necessary healthcare resources to tackle two contagious diseases at the same time. To counteract the sudden increase in TB cases, appropriate management and effective policies must be implemented. Thus, in order to prevent the spread of these infectious diseases, it is critical to recognise and address the problems that the healthcare sector faces, as well as to create an atmosphere in which the healthcare sector can function at its full potential.

Lumpy skin disease (LSD) is a viral disease that affects farm animals including water buffalo. It is caused by the contagious LSD virus, a member of the Poxiviridae family's Capripox genus. Skin sores are thought to be the most common site of infection since the virus may live for lengthy periods in lesions or scabs. The first clinical indications of LSD were described in Zambia, in 1929. Pakistan has also been afflicted by LSD, with a high number of animals infected at many cattle ranches in Karachi, 190,000 cases of LSD have been reported nationwide, with greater than 7500 deaths attributable to the illness. LSD has a huge influence on Pakistan's economic status, resulting in the loss of cattle and a decrease in milk output. The Ministry of Research and National Food Safety in Pakistan has formed a working group to create a framework for controlling the spread of LSD in cattle and buffalo. Official and private veterinarians, both field and slaughterhouse, veterinary students, farmers, cattle merchants, cattle truck drivers, and artificial inseminators should all participate in awareness efforts.

Systemic lupus erythematosus (SLE) is an autoimmune disease that can cause both direct and indirect inflammatory damage to multiple organs. Clinical symptoms in the skin, joints, kidneys, and central nervous system, as well as serological indicators such as antinuclear antibodies (ANA), notable antibodies to dsDNA, are used to diagnose SLE. mRNA SARS-CoV-2 vaccines have been shown to trigger SLE flares and the development of new rheumatic diseases. SARS-CoV-2 mRNA vaccinations increase type I interferon (INF), which is not only known to have a role in the antiviral response but is also a crucial cytokine in the pathophysiology of SLE. Furthermore, both the mRNA and adenovirus vaccines boost the production of type 1 interferons, which are required for the spread of SARS-CoV-2. The danger of not administering the COVID-19 vaccination to SLE patients is significantly larger than the likelihood of its adverse effects, which are most likely caused by intrinsic immune failure, demographic disease activity, medications, linked organ damage, and comorbidities. The adverse effects of COVID-19 vaccination in SLE patients are common (about 50%), although they do not interfere with daily functioning in the majority of cases. Several precautions can be taken to avoid the complications associated with COVID-19 vaccinations.

Background: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) frequently coexist, posing a significant challenge due to increased risks of cardiovascular disease and mortality. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have demonstrated potential for enhancing glucose control and reducing cardiovascular and renal risks. Methods: Randomized controlled trials (RCTs) were taken to compare semaglutide with placebo or standard care in adults with T2DM and CKD. Key outcomes assessed included cardiovascular mortality, major adverse cardiovascular events (MACE), kidney-related adverse events, all-cause mortality, and hospitalization rates. Results: Three RCTs involving 10 013 patients were included. Semaglutide demonstrated a 29% reduction in cardiovascular mortality (risk ratio [RR]: 0.71; 95% confidence interval [CI]: 0.52–0.97; P = 0.03; I ² = 59%) and a 20% reduction in MACE (RR: 0.80; 95% CI: 0.71–0.91; P = 0.0007; I ² = 0%). A significant 20% decrease in kidney-related adverse events was observed (RR: 0.80; 95% CI: 0.71–0.89; P < 0.0001; I ² = 0%), and semaglutide also reduced the need for cardiovascular medications (RR: 0.86; 95% CI: 0.81–0.91; P < 0.00001; I ² = 13%). Conclusion: Semaglutide shows promise as a therapeutic option for T2DM patients with CKD, significantly improving cardiovascular and renal outcomes. Its integration into treatment regimens for high-risk patients may enhance clinical outcomes and reduce treatment complexity. However, more extensive and longer-term studies are needed to confirm these findings.